Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06521801

Cardio-Renal Registry

Cardiovascular disease is the leading cause of morbidity and mortality among patients with chronic kidney disease (CKD). Even after adjustment for known cardiovascular risk factors, including diabetes and hypertension, mortality risk progressively increases with worsening CKD. As glomerular filtration rate (GFR) declines the probability of developing coronary artery disease (CAD) increases linearly, and patients with GFR <60 mL/min/1.73 m2 have 2-3-fold increased CV mortality risk, relative to patients without CKD. Management of CAD is complicated in CKD patients due to the likelihood of comorbid conditions and potential for side effects. Despite their high cardiovascular risk, ACS patients with renal dysfunction are less commonly treated with guideline-based medical therapy and are less frequently referred for coronary revascularisation. This observation, referred to as the "treatment risk paradox," has been well described and may be explained by physicians' concerns regarding possible nonrenal side effects as well as renal toxicities. Furthermore, patients with severe CKD have traditionally been under-represented in most large cardiovascular clinical trials. Therefore, recommendations for both medical and revascularisation of CAD have relied heavily on extrapolation of results from the non-CKD population.

This data will add to that literature by assessing the characteristics and outcomes of patients with CAD and CKD. It will also identify and characterise predictors of outcomes, improve risk stratification and diagnostic evaluation.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

End Stage Renal Disease Brain Diseases Cardio-Renal Syndrome Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Accident Cerebrovascular Disorders Chronic Disease Dialysis Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Heart Diseases Heart Failure Infarction Ischemia Kidney Diseases Kidney Failure, Chronic Male Urogenital Diseases Myocardial Infarction Myocardial Ischemia Necrosis Nervous System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Percutaneous Coronary Intervention Renal Insufficiency Renal Insufficiency, Chronic Stroke Urogenital Diseases Urologic Diseases Vascular Diseases

Age range

16 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Barts Health NHS Trust

London, EC1A 7BE, United Kingdom

Location status: Recruiting

Location contact

Krishnaraj Rathod, MBBS, PhD

CONTACT

[email protected]

02073777000

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Informed consent will not be sought for, as patients are automatically included onto a database that we will use for research purposes. No children will be included in this study. Vulnerable adults or those unable to give consent will be included in the study as well if they are referred to the Nephrology team.

Inclusion criteria

  • Both male and female patients ≥16 years of age will be included
  • All patients will be reviewed by the Nephrology team a the RLH with renal disease.

Exclusion criteria

  • Patients <16 years will not be included in this study.

Treatment and study plan

observation

Other

Observation

Primary outcomes

  1. Mortality

    Time frame: 30 days and 1 year

  2. Re-admission rates

    Time frame: 30 days and 1 year

  3. Major Adverse Cardiac Events

    Time frame: 30 days and 1 year

  4. Major Adverse Kidney Events

    Time frame: 30 days and 1 year

Study contacts

Contact information is provided by the study sponsor or research team.

Krishnaraj Rathod, MBBS, PhD

CONTACT

[email protected]

02073777000

Sponsors and collaborators

Lead sponsor

Queen Mary University of London

Other

Registry information

Official study title

Barts Health Cardio-Renal Registry

Acronym: BHCRR

Important dates

Study start
2024
Primary completion
2030
Study completion
2030
First posted
Jul 26, 2024
Registry last updated
Jan 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.